CRIS Current Research Information System

TESTONI, NICOLETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.699
AS - Asia 9.319
EU - Europa 8.349
AF - Africa 724
SA - Sud America 471
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 9
Totale 29.584
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.595
CN - Cina 2.704
VN - Vietnam 2.500
SG - Singapore 2.399
GB - Regno Unito 2.229
SE - Svezia 1.370
IT - Italia 1.124
DE - Germania 1.083
HK - Hong Kong 578
IN - India 478
RU - Federazione Russa 427
FR - Francia 379
BR - Brasile 343
NL - Olanda 321
IE - Irlanda 306
UA - Ucraina 263
KR - Corea 232
TG - Togo 184
ZA - Sudafrica 178
FI - Finlandia 169
CI - Costa d'Avorio 157
EE - Estonia 154
CH - Svizzera 126
BG - Bulgaria 103
JO - Giordania 94
NG - Nigeria 91
SC - Seychelles 89
JP - Giappone 85
GR - Grecia 79
CA - Canada 71
AR - Argentina 64
BE - Belgio 63
AT - Austria 45
IR - Iran 42
TR - Turchia 37
ID - Indonesia 36
PL - Polonia 27
MX - Messico 24
BD - Bangladesh 19
EC - Ecuador 18
ES - Italia 15
MY - Malesia 15
LB - Libano 13
PH - Filippine 13
PY - Paraguay 13
IQ - Iraq 12
RO - Romania 12
CL - Cile 11
UZ - Uzbekistan 11
LT - Lituania 10
AU - Australia 9
SA - Arabia Saudita 9
CZ - Repubblica Ceca 8
MA - Marocco 8
PE - Perù 8
CO - Colombia 7
EU - Europa 6
PK - Pakistan 6
PT - Portogallo 5
DZ - Algeria 4
HR - Croazia 4
KE - Kenya 4
MK - Macedonia 4
NZ - Nuova Zelanda 4
QA - Qatar 4
RS - Serbia 4
TW - Taiwan 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AL - Albania 3
BA - Bosnia-Erzegovina 3
DK - Danimarca 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
KH - Cambogia 3
KZ - Kazakistan 3
LU - Lussemburgo 3
TN - Tunisia 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BO - Bolivia 2
KG - Kirghizistan 2
LK - Sri Lanka 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PA - Panama 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AM - Armenia 1
BH - Bahrain 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GM - Gambi 1
GT - Guatemala 1
HU - Ungheria 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 29.577
Salva come PNG Salva come JPEG
Città #
Southend 2.022
Singapore 1.560
Ashburn 1.166
Chandler 1.114
Fairfield 1.069
Dong Ket 1.028
Hong Kong 573
Woodbridge 540
Houston 537
Wilmington 519
Hefei 513
Ann Arbor 496
Seattle 487
Beijing 464
Princeton 380
Cambridge 375
Ho Chi Minh City 316
Dublin 305
Santa Clara 295
Boardman 264
Hanoi 238
Seoul 217
Bologna 205
Lomé 184
Westminster 180
Nanjing 173
Padova 164
Dallas 157
Abidjan 156
New York 155
Helsinki 125
Los Angeles 117
Jacksonville 116
Berlin 114
Bern 106
Sofia 96
Turin 94
Amman 93
Jinan 93
Milan 93
Munich 91
Medford 89
Buffalo 84
Shenyang 80
Bremen 78
Saint Petersburg 76
Hebei 75
Tokyo 68
Redondo Beach 67
Abeokuta 64
Brussels 62
Florence 57
Falls Church 56
San Diego 56
Nanchang 55
Changsha 54
Frankfurt am Main 53
Falkenstein 51
Bengaluru 49
Tianjin 48
Guangzhou 47
Redwood City 41
Secaucus 41
Jiaxing 40
Redmond 39
Zhengzhou 38
Haiphong 37
Shanghai 36
Hangzhou 35
São Paulo 35
Norwalk 30
Taizhou 27
Mülheim 26
Paris 26
Toronto 25
Chicago 24
Istanbul 24
Phoenix 24
Düsseldorf 23
Hyderabad 23
Mountain View 23
Biên Hòa 22
Da Nang 22
Mahé 22
Washington 22
Chengdu 21
Jakarta 21
Lappeenranta 21
London 21
Taiyuan 21
Des Moines 20
Fuzhou 20
Haikou 20
Ningbo 20
Tongling 20
Turku 20
Yubileyny 20
Brooklyn 19
Dearborn 19
Nuremberg 19
Totale 19.266
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 663
Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery 332
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 316
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 313
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 305
14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia 280
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 276
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 270
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 269
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 262
Aggressive Aneuploid Acute Myeloid Leukemia Is Dependent on Alterations of P53, Gain of APC and PLK1 and Loss of RAD50 258
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 251
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 240
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 240
4q12 translocations with GSX2 expression identify a CD7+ acute myeloid leukaemia subset 238
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 236
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 232
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 230
Alterations in phosphatidylinositol 3-phosphate (PI3P) pathway and cAMP pathway confirm poor prognosis and reduced overall survival (OS) in a series of 209 acute myeloid leukemia patients 230
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 220
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 218
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 214
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 212
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 211
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis 211
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 210
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 206
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 206
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
A cell cycle-related genomic and transcriptomic signature distinguish aneuploid and euploid acute myeloid leukemia 200
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 199
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 198
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 194
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 194
CLINICAL OUTCOMES PREDICTION FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE-DEXAMETHASONE AND AUTOLOGOUS STEM CELL TRANSPLANTATION BY 8-GENE SIGNATURE OF CD138+ PLASMA CELLS 193
Epigenetically induced ectopic expression of uncx impairs the proliferation and differentiation of myeloid cells 193
A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia 191
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 191
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 188
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 187
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 184
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 181
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 177
Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation. 176
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 175
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 175
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 169
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 168
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 167
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 167
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 167
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 166
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 166
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 166
Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival 166
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 164
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 163
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 162
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 162
Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. 162
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 162
Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission. 161
Association of 3q21q26 syndrome with different RPN1/EVI1 fusion transcripts 161
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 161
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 158
Loss of PALB2 predicts poor prognosis in acute myeloid leukemia and suggests novel therapeutic strategies targeting the DNA repair pathway 158
NPM1 mutations are more stable than FLT3 mutations during the course of disease in patients with acute myeloid leukemia. 157
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 157
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 155
MHC-I Antigen Presentation Role in Immune Escape of Acute Myeloid Leukemia with High Burden of Genomic Aberration 153
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 153
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 152
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 152
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 152
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 152
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 151
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 151
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 150
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 150
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 150
Interleukin-12 production by leukemia-derived dendritic cells counteracts the inhibitory effect of leukemic microenvironment on T cells. 149
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 149
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 149
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 147
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 147
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 146
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 146
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 145
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 145
Prognostic significance of alterations of pathways regulating autophagy in acute myeloid leukemia 144
A New Entity of Acute Myeloid Leukemia Driven By Epigenetic and Somatic Dis-Regulation of Uncx, a Novel Homeobox Transcription Factor Gene 144
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 144
Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation 143
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 142
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up 142
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 142
CLINICAL OUTCOME OF T- ACUTE LYMPHOBLASTIC LEUKEMIA/ LYMPHOMA (T-ALL/T-LBL): THE BOLOGNA EXPERIENCE 141
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 139
Totale 19.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.071
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.071
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.462 0 0 0 0 0 132 56 196 271 116 206 1.485
2021/20224.118 560 95 232 405 372 235 70 266 176 327 700 680
2022/20234.502 496 728 239 593 316 382 127 234 701 112 377 197
2023/20241.259 65 166 74 141 87 315 67 102 34 75 77 56
2024/20254.697 158 609 379 323 531 181 531 157 34 471 253 1.070
2025/20265.461 968 1.471 924 726 1.112 260 0 0 0 0 0 0
Totale 30.140